EGFR and non-small cell lung carcinoma: It is used as a first-line treatment for patients with locally advanced or metastatic non-small cell lung carcinoma (NSCLC) with EGFR sensitizing mutations and as a treatment for patients with EGFR T790M-mutation-positive NSCLC that has progressed on or after EGFR-TKI therapy.